Sign In

Login

Password

Forgot Password ? Sign Up

Agomelatin (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Agomelatin" in German language version.

refsWebsite
Global rank German rank
13nih.gov
4th place
7th place
2doi.org
2nd place
3rd place
2europa.eu
68th place
29th place
2akdae.de
low place
1,853rd place
2web.archive.org
1st place
1st place
1sigmaaldrich.com
924th place
87th place
1fachinfo.de
low place
2,942nd place
1espacenet.com
800th place
160th place
1clinicaltrials.gov
5,225th place
2,461st place

akdae.de

clinicaltrials.gov

doi.org

  • S. Yous, J. Andrieux, H. E. Howell, P. J. Morgan, P. Renard, B. Pfeiffer, D. Lesieur, B. Guardiola-Lemaitre: Novel naphthalenic ligands with high affinity for the melatonin receptor. In: J. Med. Chem. 35. Jahrgang, Nr. 8, 1992, S. 1484–1486, doi:10.1021/jm00086a018.
  • Christian Markl, Darius Zlotos: A Novel Synthesis of the Antidepressant Agomelatine. In: Synthesis. 2011, 2011, S. 79, doi:10.1055/s-0030-1258968.

espacenet.com

worldwide.espacenet.com

  • Patent EP2151429B1: Verfahren zur Herstellung von Agomelatin. Angemeldet am 4. August 2009, veröffentlicht am 25. Mai 2011, Anmelder: Servier Lab, Erfinder: Christophe Hardouin, Jean-Pierre Lecouve.‌

europa.eu

ema.europa.eu

fachinfo.de

nih.gov

ncbi.nlm.nih.gov

  • Audinot, V., F. Mailliet, et al. (2003). New selective ligands of human cloned melatonin MT1- und MT2 receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 367: 553-561. PMID 12764576
  • San, L. Arranz, B (2008). Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 23(6): 396–402, PMID 18583104.
  • Millan, M. J., A. Gobert, et al. (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306(3): 954–964, PMID 12750432.
  • Loo H et al., In: Int Clin Psychopharmacol. 2002;17:239–247, PMID 12177586.
  • Kennedy SH, Emsley R, Europ. Neuropsychopharmacol 2006;16:93–100, PMID 16249073.
  • Olié JP, Kasper S, Int. J. Neuropsychopharmacol 2007;10(5):661-73, PMID 17477888.
  • Hale, A., R. Corral, et al. (2010). Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol e-pub ahead of print, PMID 20856123.
  • Lemoine, P., C. Guilleminault, et al. (2007). "Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine." J Clin Psychiatry 68(11): 1723–1732, PMID 18052566.
  • Kennedy, S. H., S. Rizvi, et al. (2008). A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 28(3): 329–333, PMID 18480691.
  • Kasper, S., G. Hajak, et al. (2010). "Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline." J Clin Psychiatry 71(2): 109–120, PMID 20193645.
  • Goodwin, G. M., R. Emsley, et al. (2009). Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70(8): 1128–1137, PMID 19689920.
  • Montgomery SA et al., Int Clin Psychopharmacol. 2004 Sep;19(5):271-280, PMID 15289700.
  • Servier and Novartis sign licensing agreement for agomelatine; Meldung von Servier, PMID 18457470.

sigmaaldrich.com

web.archive.org